文献速递青光眼角膜与眼表疾病

比马前列素植入剂治疗开角型青光眼与高眼压的3期随机20个月研究(ARTEMIS 1)

Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
PubMed 文献 · Ophthalmology · 2020-06-13

这项3期随机对照研究纳入开角型青光眼或高眼压成人受试者,比较10 μg与15 μg比马前列素植入剂(第1天给药,第16、32周重复给药)与每日两次0.5%马来酸噻吗洛尔滴眼液的疗效与安全性。两种剂量植入剂在每次给药后降眼压效果均非劣于噻吗洛尔;但角膜和炎症相关治疗中出现的不良事件发生率植入剂高于噻吗洛尔,且15 μg剂量最高,重复治疗后角膜不良事件增加。风险-获益评估倾向于10 μg植入剂优于15 μg植入剂。

要点

  • 10 μg与15 μg比马前列素植入剂降眼压效果在每次给药后均非劣于噻吗洛尔。
  • 植入剂角膜和炎症相关不良事件发生率高于噻吗洛尔,15 μg剂量最高。
  • 固定16周间隔给药3次后,≥20%角膜内皮细胞密度丢失发生率10 μg为10.2%、15 μg为21.8%。

核心结论

  • 两种剂量比马前列素植入剂均达到主要终点,即至第12周降眼压效果非劣于噻吗洛尔。
  • 3次给药后1年,多数受试者无需额外治疗即可控制眼压。
  • 风险-获益评估倾向于10 μg植入剂优于15 μg植入剂。

研究设计与样本

  • 随机、20个月、多中心、受试者和疗效评估者设盲、平行组、3期临床研究。
  • 受试者为双眼开角型青光眼或高眼压成人,研究眼下方虹膜角膜角开放,洗脱后研究眼基线眼压(0小时;上午8点)为22-32 mmHg。
  • 研究眼第1天接受10 μg(n=198)或15 μg(n=198)比马前列素植入剂,并于第16周和第32周重复给药,或接受每日两次0.5%马来酸噻吗洛尔(n=198)。
  • 每次访视在0小时和2小时测量眼压。

主要发现

  • 10 μg植入剂、15 μg植入剂和噻吗洛尔组基线平均日间眼压分别为24.0、24.2和23.9 mmHg。
  • 至第12周,10 μg植入剂、15 μg植入剂和噻吗洛尔组平均日间眼压范围分别为16.5-17.2、16.5-17.0和17.1-17.5 mmHg。
  • 角膜和炎症相关治疗中出现的不良事件(如角膜内皮细胞丢失、虹膜炎)发生率植入剂高于噻吗洛尔,且15 μg剂量最高。
  • 重复治疗后角膜治疗中出现的不良事件发生率增加;固定16周间隔给药3次后,≥20%角膜内皮细胞密度丢失发生率10 μg植入剂为10.2%、15 μg植入剂为21.8%。
  • 平均最佳矫正视力保持稳定;3例接受植入剂治疗且发生角膜治疗中出现的不良事件的受试者在末次访视时最佳矫正视力下降超过2行。

关键数值与推荐

  • 主要终点为至第12周的眼压及基线眼压变化。
  • 安全性指标包括治疗中出现的不良事件和角膜内皮细胞密度。

临床怎么用

  • 比马前列素植入剂有望改善青光眼治疗依从性并减轻治疗负担。
  • 鉴于风险-获益评估倾向于10 μg植入剂,临床选择剂量时需权衡降眼压获益与角膜内皮细胞丢失等角膜不良事件风险。
  • 正在进行的研究评估其他给药方案以减少角膜内皮细胞密度丢失的潜在风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10- and 15-μg bimatoprost implant in subjects with open-angle glaucoma (OAG) and ocular hypertension (OHT) after initial and repeated administrations. DESIGN: Randomized, 20-month, multicenter, subject- and efficacy evaluator-masked, parallel-group, phase 3 clinical study. PARTICIPANTS: Adults with OAG or OHT in each eye, open iridocorneal angle inferiorly in the study eye, and study eye baseline IOP (hour 0; 8 am) of 22-32 mmHg after washout. METHODS: Study eyes received bimatoprost implant 10 μg (n = 198) or 15 μg (n = 198) on day 1 with readministration at weeks 16 and 32, or twice-daily topical timolol maleate 0.5% (n = 198). Intraocular pressure was measured at hours 0 and 2 at each visit. MAIN OUTCOME MEASURES: Primary end points were IOP and change from baseline IOP through week 12. Safety measures included treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD). RESULTS: Both dose strengths of bimatoprost implant were noninferior to timolol in IOP lowering after each administration. Mean diurnal IOP was 24.0, 24.2, and 23.9 mmHg at baseline and from 16.5-17.2, 16.5-17.0, and 17.1-17.5 mmHg through week 12 in the 10-μg implant, 15-μg implant, and timolol groups, respectively. The incidence of corneal and inflammatory TEAEs of interest (e.g., corneal endothelial cell loss, iritis) was higher with bimatoprost implant than timolol and highest with the 15-μg dose strength. Incidence of corneal TEAEs increased after repeated treatment; with 3 administrations at fixed 16-week intervals, incidence of ≥20% CECD loss was 10.2% (10-μg implant) and 21.8% (15-μg implant). Mean best-corrected visual acuity (BCVA) was stable; 3 implant-treated subjects with corneal TEAEs had >2-line BCVA loss at their last visit. CONCLUSIONS: Both dose strengths of bimatoprost implant met the primary end point of noninferiority to timolol through week 12. One year after 3 administrations, IOP was controlled in most subjects without additional treatment. The risk-benefit assessment favored the 10-μg implant over the 15-μg implant. Ongoing studies are evaluating other administration regimens to reduce the potential for CECD loss. The bimatoprost implant has potential to improve adherence and reduce treatment burden in glaucoma.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Medeiros FA, Walters TR, Kolko M, et al. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1). Ophthalmology. 2020. PMID: 32544560. doi:10.1016/j.ophtha.2020.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。